This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 43475 results found since Jan 2013.

Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo
Conclusions: Our findings demonstrate that there is an imbalanced uptake of [11C]raclopride during the headache attack and ictal allodynia, which indicates reduction and fluctuation in ictal endogenous DA release in migraineurs. Moreover, the longer the history and recurrence of migraine attacks, the lower the ictal endogenous DA release.
Source: Neurology - April 24, 2017 Category: Neurology Authors: DaSilva, A. F., Nascimento, T. D., Jassar, H., Heffernan, J., Toback, R. L., Lucas, S., DosSantos, M. F., Bellile, E. L., Boonstra, P. S., Taylor, J. M. G., Casey, K. L., Koeppe, R. A., Smith, Y. R., Zubieta, J.-K. Tags: Migraine, PET, Central pain, Basal ganglia ARTICLE Source Type: research

Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine
Ophthalmoplegic migraine (OM) is a rare form of migraine characterized by recurrent episodes of headache with ophthalmoplegia related to paresis of cranial nerves III, IV, or VI.1 Adult onset of ophthalmoplegic migraine is rare as patients usually have a history of typical migraine headaches early in life in addition to a positive family history.2 OM is a diagnosis of exclusion requiring appropriate laboratory test and neuroimaging studies to ensure an accurate diagnosis.3 In most cases of OM, there is a transient enhancement of the apparent origin of the oculomotor nerve.1,4 The recent revision of the International Headac...
Source: Neurology Clinical Practice - October 16, 2017 Category: Neurology Authors: Qureshi, I. A., Rodriguez, G. J., Cruz-Flores, S., Maud, A. Tags: Migraine, MRI Case Source Type: research

Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine
Conclusions MBCT-M is a promising treatment for reducing headache-related disability, with greater benefits in episodic than CM. Trial Registration Information ClinicalTrials.gov Identifier: NCT02443519. Classification of Evidence This study provides Class III evidence that MBCT-M reduces headache disability to a greater extent in people with episodic than CM.
Source: Neurology Clinical Practice - June 7, 2021 Category: Neurology Authors: Seng, E. K., Conway, A. B., Grinberg, A. S., Patel, Z. S., Marzouk, M., Rosenberg, L., Metts, C., Day, M. A., Minen, M. T., Buse, D. C., Lipton, R. B. Tags: Migraine, All Neuropsychology/Behavior, Clinical trials Randomized controlled (CONSORT agreement) Research Source Type: research

A randomized controlled trial of intranasal ketamine in migraine with prolonged aura
Conclusions: These data provide translational evidence for the potential importance of glutamatergic mechanisms in migraine aura and offer a pharmacologic parallel between animal experimental work on cortical spreading depression and the clinical problem. Classification of evidence: This study provides Class III evidence that intranasal ketamine is effective in reducing aura severity in patients with migraine with prolonged aura.
Source: Neurology - February 11, 2013 Category: Neurology Authors: Afridi, S. K., Giffin, N. J., Kaube, H., Goadsby, P. J. Tags: Migraine, Clinical trials Randomized controlled (CONSORT agreement), Class III ARTICLE Source Type: research

Migraine and structural changes in the brain: A systematic review and meta-analysis
Conclusion: These data suggest that migraine may be a risk factor for structural changes in the brain. Additional longitudinal studies are needed to determine the differential influence of migraine without and with aura, to better characterize the effects of attack frequency, and to assess longitudinal changes in brain structure and function.
Source: Neurology - September 30, 2013 Category: Neurology Authors: Bashir, A., Lipton, R. B., Ashina, S., Ashina, M. Tags: Migraine, MRI VIEWS & amp;amp; REVIEWS Source Type: research

Headache-related health resource utilisation in chronic and episodic migraine across six countries
Conclusions Headache-related resource usage differed significantly between the USA and other countries. US respondents were generally less likely to report recent provider visits and use of prescription-acute treatments. They were more likely to report emergency department visits than in European countries, but less likely to report hospitalisation than in Canada and Australia.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 13, 2013 Category: Neurosurgery Authors: Sanderson, J. C., Devine, E. B., Lipton, R. B., Bloudek, L. M., Varon, S. F., Blumenfeld, A. M., Goadsby, P. J., Buse, D. C., Sullivan, S. D. Tags: Open access, Headache (including migraine), Pain (neurology) Source Type: research

Midlife migraine and late-life parkinsonism: AGES-Reykjavik Study
Conclusions: These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are needed to identify candidate pathways that may account for the comorbid constellation of symptoms.
Source: Neurology - September 29, 2014 Category: Neurology Authors: Scher, A. I., Ross, G. W., Sigurdsson, S., Garcia, M., Gudmundsson, L. S., Sveinbjornsdottir, S., Wagner, A. K., Gudnason, V., Launer, L. J. Tags: Migraine, Parkinson's disease/Parkinsonism, Restless legs syndrome, Brain trauma, All epidemiology ARTICLE Source Type: research

Association of Migraine Disorders Resident Research Award
The purpose of this grant is to stimulate original resident research in migraine-related head and neck disorder projects that are well-conceived and scientifically valid, with the potential to advance the understanding of migraine disease. ELIGIBILITY Any resident of an accredited training program is eligible to apply for the AMD's Resident Research Grant(s). There are no restrictions on country of residence. Applications submitted by ineligible PIs will NOT be reviewed by the CORE Study Section. CONDITIONS Proposed projects may be related to any area of migraine-related head and neck disorders. Proposed pro...
Source: ScanGrants feed - October 8, 2014 Category: Research Authors: Association of Migraine Disorders Source Type: funding

TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp
The transient receptor potential vanilloid type-1 receptor (TRPV1) is a non-selective, ligand-gated cation channel expressed in small sensory neurons.1 It responds to noxious heat, protons and capsaicin and it is preferentially expressed in small sensory neurons.2 3 Trigeminal nociceptive neurons contain glutamate, substance P (SP) and calcitonin gene-related peptide (CGRP). TRPV1 receptors evoke CGRP release; inhibition prevents and reverses central sensitisation. BoNT/A has analgesic effects on capsaicin-evoked pain. It is effective in chronic migraine treatment.4 BoNT/A decreases TRPV1-positive neurons in the rat trigem...
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2015 Category: Neurosurgery Authors: Silberstein, S. D. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Headache (including migraine), Pain (neurology), Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases Editorial commentaries Source Type: research

Comment: Altered sphingolipid metabolism--A marker for episodic migraine?
A biological marker for migraine would be of great value in clinical practice. This collaborative study evaluated interictal, circulating sphingolipids in 52 female patients with episodic migraine compared with 36 women who did not have headaches. Total ceramide and its precursor, dihydroceramide, were decreased in the migraineurs as compared with controls, and, furthermore, some very long sphingomyelin species were increased in those with migraine. The authors suggest that serum sphingolipid panels have the potential to differentiate patients with episodic migraine from controls.
Source: Neurology - October 5, 2015 Category: Neurology Authors: Ekbom, K. Tags: Migraine ARTICLE Source Type: research

Delayed diagnosis of cadasil in a patient with hemiplegic migraine
Conclusion prevalence of CADASIL may be underestimated partly due to underdiagnoses, especially in patients presenting with migraine. Every attempt to gain an appropriate family history should be made to avoid misdiagnosis.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Matar, M., Sivagnanasundarum, J., Harikrishnan, S. Tags: Headache (including migraine), Stroke Thur 21, Parallel session 5: Therapeutics Source Type: research

Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome
Conclusions: After controlling for nausea and other factors, headache exacerbation with DHE infusions is not an independent predictor of poor headache outcome and clinicians should not interpret its presence as a reason to stop treatment. The focus of management should be on controlling nausea as it is the most important modifiable factor in achieving a good headache outcome with an inpatient course of IV DHE for chronic migraine.
Source: Neurology - February 29, 2016 Category: Neurology Authors: Eller, M., Gelfand, A. A., Riggins, N. Y., Shiboski, S., Schankin, C., Goadsby, P. J. Tags: Migraine, Class IV ARTICLE Source Type: research

Transcranial Direct Current Stimulation and Transcutaneous Occipital Nerve Stimulation in Chronic Migraine: A Pilot-Comparison of Therapeutic and Electrophysiological Effects (I3.008)
Conclusions:Cathodal visual cortex tDCS and tONS may thus be interesting options for the non-invasive treatment of CM. The effect size seems close to that seen with Botox or topiramate, but it remains to be confirmed in a RCT. Only tONS was able to induce recordable changes in visual cortex responsivity. Supported by FP7-EUROHEADPAIN 602633Disclosure: Dr. Schoenen has nothing to disclose. Dr. D'Ostilio has nothing to disclose. Dr. Cosseddu has nothing to disclose. Dr. Nonis has nothing to disclose. Dr. Sava has nothing to disclose. Dr. Magis has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Schoenen, J., D'Ostilio, K., Cosseddu, A., Nonis, R., Sava, S., Magis, D. Tags: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders Data Blitz Presentations Source Type: research

Predictors of Inadequate 24-Hour Sustained Response in Episodic Migraine: Results from American Migraine Prevalence and Prevention Study (AMPP) (I3.013)
CONCLUSIONS: Among migraineurs reporting 2hPF, adequate 24hSPR was common (74.3[percnt]). However, 25.7[percnt] reported return of headache. Persons with frequent headache, allodynia, depression and medication overuse may be susceptible to return of headache despite a robust 2hPF response. Study Supported By: Promius PharmaDisclosure: Dr. Munjal has received personal compensation for activities with Promius Pharma as an employee. Dr. Reed has received personal compensation for activities with Allergan, Inc., Colucid, Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil. Dr. Buse...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Munjal, S., Reed, M., Buse, D., Bennett, A., Fanning, K., Lipton, R. Tags: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders Poster Presentations Source Type: research

The migraine postdrome: An electronic diary study
Conclusion: Nonheadache symptoms in the postdrome were common and may contribute to the distress and disability in the patients studied. Postdrome symptoms merit larger observational studies and careful recording in clinical trials of acute and preventive migraine treatments.
Source: Neurology - July 17, 2016 Category: Neurology Authors: Giffin, N. J., Lipton, R. B., Silberstein, S. D., Olesen, J., Goadsby, P. J. Tags: Migraine, All Clinical Neurology ARTICLE Source Type: research